Gagnon Securities LLC bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 3,168 shares of the biopharmaceutical company’s stock, valued at approximately $272,000. Several other hedge […]
Philadelphia Trust Co. trimmed its position in Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) by 12.5% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 92,120 shares of the biopharmaceutical company’s stock after selling 13,210 shares during the period. Gilead Sciences comprises 0.8% of Philadelphia Trust […]
AlphaCentric Advisors LLC decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) by 37.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,500 shares of the biopharmaceutical company’s stock after selling 5,000 shares during the period. AlphaCentric […]
Should You Buy or Sell Gilead Sciences Stock? Get The Latest GILD Stock Forecast, Price Target, Dividend Info, Headlines, Short Interest at MarketBeat.
Summit Trail Advisors LLC cut its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) by 12.0% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 5,915 shares of the biopharmaceutical company’s stock after selling 810 shares during the period. […]